Publication Spotlight:
Hyperglycosylation is a Metabolic Driver of Alzheimer's Disease
We are pleased to highlight a groundbreaking new publication in Nature Metabolism titled "Hyperglycosylation is a Metabolic Driver of Alzheimer's Disease" by Hawkinson et al. This study provides compelling evidence that altered glycan metabolism is not merely a consequence of neurodegeneration but may actively contribute to Alzheimer's disease (AD) progression.
Using an integrated spatial multiomics approach combining metabolomics, lipidomics, and glycomics, researchers analyzed both human Alzheimer's disease brain tissue and established mouse models of AD. Their findings revealed a conserved pattern of elevated N-glycosylation throughout affected brain regions, identifying hyperglycosylation as a previously underappreciated metabolic hallmark of disease progression.
|
|
This research advances our understanding of Alzheimer's disease by demonstrating that:
- Hyperglycosylation is consistently observed in both human AD brain tissue and multiple AD mouse models
- Glycan abundance increases as disease severity progresses, suggesting a direct relationship between N-glycosylation and neurodegeneration
- Increased glycan biosynthesis, rather than impaired glycan turnover, appears to drive the hyperglycosylation phenotype
- Reducing glycan biosynthesis in AD mouse models improved cognitive outcomes, while increasing glycosylation through glucosamine supplementation worsened disease-associated behavioral deficits
|
|
|
|
| These findings position glycan metabolism as a promising new avenue for therapeutic intervention in Alzheimer's disease. |
How Spatial Glycomics Enabled These Discoveries |
A key strength of this study was the use of advanced spatial glycomics workflows to visualize and quantify N-glycan distributions directly within brain tissue. By combining PNGaseF PRIMETM mediated glycan release with MALDI mass spectrometry imaging, researchers were able to map glycan abundance across distinct brain regions and correlate glycosylation patterns with disease progression.
This spatial approach revealed progressive glycan accumulation in Alzheimer's disease tissues and provided critical insight into how glycosylation changes occur within the complex architecture of the brain. |
|
Advancing Neurodegenerative Disease Research Through Glycomics |
| As the field increasingly recognizes the importance of metabolism in neurodegenerative disorders, this publication highlights the critical role of glycosylation as a biological driver of disease. The ability to accurately characterize spatial N-glycan patterns is opening new opportunities for biomarker discovery, mechanistic understanding, and therapeutic development in Alzheimer's disease and other neurological disorders. |
|
|
|
At N-Zyme Scientifics, we are proud to support researchers advancing the frontiers of glycoscience through high-performance enzyme solutions designed for spatial glycomics and glycoproteomics workflows. |
Learn more about how PNGaseF PRIMETM can support your glycomics and spatial biology research |
|
|
|
_10.jpg)
